IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund

Retirement savers who never chose IDEXX Laboratories (NASDAQ:IDXX | IDXX Price Prediction) got a lift from it anyway on Monday. The veterinary diagnostics company was up 20.2% in the regular session as of 1:54 PM ET, trading at $662.55, after its third-quarter earnings report beat estimates and raised full-year guidance. In later trading the stock sat at $662.27. It closed the prior session at $551.21 and touched an intraday high of $668.54.

IDEXX is an S&P 500 component, so the gain went straight into the index funds held in millions of 401(k)s and IRAs. How much it counted to you depends on which funds you own and how much of each fund IDEXX takes up.

Earnings Beat and Guidance Raise Drove the Rally

IDEXX reported GAAP EPS of $4.01. That beat the $3.716 consensus and marked the company’s 7th consecutive EPS beat. Revenue of $1.214B came in ahead of the $1.192B consensus and grew 9.9% YoY. Gross margin expanded 110 bps to 62.9%, and operating margin rose 100 bps to 33.1%.

The growth came in a weak market for vet visits. U.S. same-store clinical visits fell an estimated 1.8%, but CAG Diagnostics recurring revenue still grew 11% organically, and VetLab consumables rose 15% organically. Barron’s described IDEXX as a pet diagnostics company defying an industry slump. Chief Executive Mike Erickson told analysts that “our growth doesn’t rely on seeing positive visits. We can grow irrespective of that.”

Management now expects 2026 revenue of $4.741B to $4.767B, up from $4.700B to $4.745B, and EPS of $14.96 to $15.16, up from $14.69 to $14.94. The weak spot was margins. The operating margin outlook of 32.1% to 32.3% was brought down to reflect costs from the acquisition of CoVet, an AI clinical assistant for veterinary teams. The chief financial officer, Andrew Emerson, said the deal carries “about 30 basis points of operating margin impact” across the third and fourth quarters.

Broad S&P 500 Funds Feel Only a Ripple

The SPDR S&P 500 ETF Trust (NYSEARCA:SPY), iShares Core S&P 500 ETF (NYSEARCA:IVV), and Vanguard S&P 500 ETF (NYSEARCA:VOO) all track the index, so all three own IDEXX. They weight each company by market value. IDEXX, whose market cap is about $52.2B, is not one of SPY’s 10 largest holdings. That list is led by NVIDIA at 7.58%, Apple at 6.66% and Microsoft at 4.91% of net assets.

The fund data available here does not give IDEXX’s exact weight in these funds, but its position is far smaller than any of those leaders. For a broad index fund holder, a 20% jump in one small position barely moves the fund’s value, so the day’s return still depends mostly on the megacap tech names at the top.

Healthcare Sector Funds Get a Bigger Dose

A sector fund is a different story. As of June 30, 2026, the Health Care Select Sector SPDR Fund (NYSEARCA:XLV) held 557,240 IDEXX shares worth about $293.4 million. That was roughly 0.72% of net assets, about the same as Becton Dickinson at 0.73%.

That weight makes IDEXX’s surge easier to see in XLV than in a broad fund. Still, XLV is driven by much bigger positions: Eli Lilly at 16.51% and Johnson & Johnson at 10.64%. A simple rule of thumb: the bigger a stock’s share of a fund, the more that stock’s move shows up in your balance.

Overlap Risk Is Easy to Miss

Many retirement investors own an S&P 500 fund in a 401(k), a total-market fund in an IRA and a healthcare sector fund on top of that. Each one may hold IDEXX. This overlap helps on a day like today, but it works the same way in a sell-off. Holding the same companies through several funds can leave you more concentrated than your list of funds suggests.

The fix is simple. Fund fact sheets list each fund’s holdings and weights, and adding up your exposure across accounts shows where your money actually sits. For most diversified savers, one mid-sized healthcare name rising or diving matters far less than overlap in the megacaps at the top of every broad index.

What to Watch Next

IDEXX will show its next point-of-care analyzer, IDEXX MultiCue Dx, at an investor session at VMX on Monday, January 18. Hemangiosarcoma detection is being added to IDEXX Cancer Dx, with broad North American availability planned beginning in the first quarter. Those launches, how CoVet is integrated into the business and margin trends are the key items to track. The stock also carries a trailing P/E of about 41, so expectations are high going into the next earnings report.

Contact [email protected] for any questions or corrections.